人工耳蜗植入术后听力保护药物的研究进展  

The Progress of Hearing-Protective Medications after Cochlear Implantation

作　　者：温家康 刘勇智 

机构地区：[1]内蒙古医科大学内蒙古临床医学院,内蒙古 呼和浩特

出　　处：《临床医学进展》2023年第8期13586-13592,共7页Advances in Clinical Medicine

摘　　要：如今,人工耳蜗已不仅可以帮助失聪患者恢复听觉,中度至重度听力损失或在较低频率上有一定程度的残余听力的患者也可以通过单侧的人工耳蜗电刺激与声学刺激相结合获得听力改善。但在手术后的几个月内,由于电极插入的创伤、炎症和耳蜗植入体相关的异物反应等原因,与功能相关的低频听力会立即出现明显损失。本篇综述将回顾人工耳蜗植入术及术后听力损伤的理论基础并对针对此损伤产生保护作用并在一定程度上改善预后的相关药物及治疗方式展开论述,拟为人工耳蜗术后听力保护提供系统性理论依据。Nowadays, cochlear implants (CI) can restore hearing not only in deaf patients, but also in patients with moderate to severe hearing loss or some level of residual hearing at lower frequencies, who access the benefits of improved hearing outcomes via electrical stimulation from a CI alone or in combination with an acoustic “hybrid” component. However, significant functionally relevant loss of low-frequency hearing is immediately apparent within the first few months of surgery, owing to the electrode insertion trauma, inflammation, and the implant-associated foreign body. This review will review the theoretical basis of cochlear implantation and postoperative hearing injury, and discuss the related drugs and treatment methods that can protect against this injury and improve the prognosis to a certain extent, and is intended to provide a systematic theoretical basis for hearing protection after cochlear implantation.

关 键 词：人工耳蜗 听力保护 内耳治疗 

分 类 号：R76[医药卫生—耳鼻咽喉科]